Catecholaminergic polymorphic ventricular tachycardia primary prevention

Catecholaminergic polymorphic ventricular tachycardia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Catecholaminergic polymorphic ventricular tachycardia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Exercise Stress Testing
Genetic Testing
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Implantable Cardioverter-Defibrillator
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Catecholaminergic polymorphic ventricular tachycardia primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Catecholaminergic polymorphic ventricular tachycardia primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Catecholaminergic polymorphic ventricular tachycardia primary prevention
CDC on Catecholaminergic polymorphic ventricular tachycardia primary prevention
Catecholaminergic polymorphic ventricular tachycardia primary prevention in the news
Blogs on Catecholaminergic polymorphic ventricular tachycardia primary prevention
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Catecholaminergic polymorphic ventricular tachycardia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Primary Prevention

There are no effective measures for the primary prevention of catecholaminergic polymorphic ventricular tachycardia.
However, there are preventive measures for episodes of catecholaminergic polymorphic ventricular tachycardia, which include:

• Lifestyle modifications:
  1. Limit or avoid competitive sports
  2. Limit or avoid strenuous exercises
  3. Limit exposure to stressful environments
• Holter monitoring: It helps in keeping the heart-rate within a safe range during physical activity.
• Compliance with medical therapy.
• Follow-up visits with a cardiologist every six to twelve months to monitor the efficacy of therapy.